Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Octopus AIM VCT plc Net Asset Value Octopus AIM VCT plc announces that as at 20 April 2026 the unaudited net asset value of the Ordinary shares was approximately 41.5 pence per share. For further...
-
Octopus AIM VCT 2 plc Net Asset Value Octopus AIM VCT 2 plc announces that as at 20 April 2026 the unaudited net asset value of the Ordinary shares was approximately 33.1 pence per share. For...
-
CASCAIS, Portugal, April 22, 2026 (GLOBE NEWSWIRE) -- Pulsar Helium Inc. (AIM: PLSR, TSXV: PLSR, OTCQB: PSRHF) (“Pulsar” or the “Company”), a primary helium company, is pleased to announce that its...
-
Endeavour Mining plc (“the Company”) announces that it received the following notification from BlackRock, Inc of its interests in the Company as at 20 April 2026 TR-1: Standard form for notification...
-
Kenmare Resources plc(“Kenmare” or the “Company” or the “Group”) 22 April 2026 Q1 2026 Production Report Kenmare Resources plc (LSE:KMR, ISE:KMR), one of the leading global producers of titanium...
-
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- 21shares, one of the world’s largest issuers of cryptocurrency exchange traded products (ETPs), today announced its expected distribution dates of...
-
Nokia OyjPörssitiedote21.4.2026 klo 20.00Muutokset Nokia Oyj:n omien osakkeiden omistuksessa Espoo – Nokia on tänään luovuttanut 121 013 yhtiön hallussa ollutta Nokian osaketta (NOKIA)...
-
Nokia CorporationStock Exchange Release21 April 2026 at 20:00 EESTChanges in Nokia Corporation's own shares Espoo, Finland – A total of 121 013 Nokia shares (NOKIA) held by the company were...
-
Transaction in Own Shares 21 April 2026 • • • • • • • • • • • • • • • • Shell plc (the ‘Company’) announces that on 21 April 2026 it purchased the following number of Shares for cancellation. ...
-
Presentation of additional analyses from FAP-Exd (AVA6103) study shows robust activity in PDX models with low FAP expression and more favorable kinetic profile compared to the marketed antibody-drug...